Addressing Critical Questions in Ovarian Cancer Research and Treatment

October 1-4, 2017
Wyndham Grand Pittsburgh
Pittsburgh, Pennsylvania

Conference Cochairs
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas
Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • View Program
  • Watch this message from Conference Cochairs Robert C. Bast, Jr. and Ursula A. Matulonis


Over the last two years, progress has been made in the treatment of ovarian cancer, but critical unanswered questions remain. For example, some ovarian cancers, specifically high-grade serous ovarian cancers, are particularly susceptible to PARP inhibitors, and as many as 50% of HGSCs have underlying defects in DNA repair. Identification of predictors of PARP inhibitor response and resistance, elucidation of PARP inhibitor resistance mechanisms, and the rationale for combination-therapy strategies to enhance the effectiveness of PARP inhibitors are all important unanswered questions. Other important topics include improvement of early-detection testing and identification of high-risk individuals. In addition, new knowledge has emerged in DNA damage and repair, metabolic changes in ovarian cancer cells and stroma, tumor microenvironment, autophagy, and the genotype and phenotype of rare ovarian cancers. How can we apply this knowledge to more effective control of ovarian cancer?

Join us this October as we present the latest advances in the research and treatment of ovarian cancer and, together, address and discuss critical questions to propel the field forward.

Lead Supporter


Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available